Drug-Delivery CRO Courts Cash-Strapped Biotech Startups

Integral BioSystems LLC, a Boston-area drug delivery contract research organization, is opening fast-track development packages to startups, fledgling companies and entrepreneurs. Integral BioSystems is offering fast-track packages to startups and fledging companies to rapidly develop analytical methods and formulation compositions to obtain additional preclinical assurance of their concepts. The company frames the move as a response to tighter startup funding conditions.

A Response to Tighter Funding Conditions

The company cites current uncertainty in the accessibility of startup investment funds to enable groundbreaking research into proof-of-concept testing in the clinic as the rationale behind the offer. Founded in 2009, Integral BioSystems says it has built up capabilities over more than a decade that it can now direct toward smaller, budget-constrained clients rather than only larger pharmaceutical partners.

Since its inception in 2009, the company has gained credibility in developing numerous drug compositions in areas of ophthalmology, dermatology, intranasal, otic and injectables. Its scientific staff work across small molecules, proteins and gene therapies, and the firm says it has already worked with a number of early-stage companies on their development paths.

Integral BioSystems scientists collectively have decades of experience in the design of sustained release injectables, such as microspheres with encapsulated DNA, proteins or small molecules. The company also says it owns turn-key methods for residual solvent and moisture analysis, and equipment to perform spray-drying, lyophilized, or suspension products.

"We have already aided and advised numerous companies to meet their development goals; quite a few of these companies have completed or, are planning proof-of-concept clinical studies."

— Dr. Shikha P. Barman, President and CEO, Integral BioSystems LLC

What the Offer Covers

Integral also offers turn-key testing services such as particle sizing and stability testing. Founder, President and CEO Dr. Shikha P. Barman, who has more than 30 years of experience in tissue-targeted, sustained release pharmaceutical formulation development, and R&D Head Kevin Ward are named as available to discuss projects at any early stage. The company says it will consider work regardless of scale or client budget.

The wider context is a biopharma funding environment that has grown less forgiving for the earliest-stage companies. Data tracked by J.P. Morgan found that 50 seed and series A investments collectively worth $2.3 billion were completed over the first three months of 2026, a pullback that industry reporting has described as putting first-time financings on course for their weakest showing since before the pandemic. Separate BioPharma Dive data indicate that capital has continued to concentrate on later-stage, better-validated programs even as overall venture totals recovered, leaving newer entrants competing harder for a shrinking pool of early-stage checks. A CRO offering to absorb some preclinical development cost or timeline risk speaks directly to that gap, giving cash-constrained founders a way to generate data before committing to a full funding round.

Integral BioSystems describes itself as a specialty drug delivery contract research organization serving both small molecule and large molecule drug candidates. The company offers contract services to pharmaceutical companies to develop drug products through CMC offerings in analytical method development, formulation development, process development, scale-up and technology transfer, and also partners with pharmaceutical companies to co-develop products based on its proprietary pharmaceutical delivery systems. It says its dosage forms are customized to achieve sustained release, targeted tissue-focused delivery, or fast-release and instant delivery, depending on the desired product attributes.

The offer positions a mid-sized CRO as a stopgap for founders unable to secure early capital on their own terms. Whether the arrangement translates into signed contracts will depend on how many cash-strapped teams take up the invitation, and on how the broader early-stage funding market moves through the rest of 2026. For now, the announcement signals that service providers, not just investors, are adjusting to a leaner startup landscape.